Kimberley Lewis1, Joshua Piticaru2, Dipayan Chaudhuri2, John Basmaji3, Eddy Fan4, Morten Hylander Møller5, John W Devlin6, Waleed Alhazzani7. 1. Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. 2. Department of Medicine, McMaster University, Hamilton, ON, Canada. 3. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. 4. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada. 5. Department of Intensive Care, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. 6. School of Pharmacy, Northeastern University, Boston, MA; Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA. 7. Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. Electronic address: waleed.al-hazzani@medportal.ca.
Abstract
BACKGROUND: Although clinical studies have evaluated dexmedetomidine as a strategy to improve noninvasive ventilation (NIV) comfort and tolerance in patients with acute respiratory failure (ARF), their results have not been summarized. RESEARCH QUESTION: Does dexmedetomidine, when compared with another sedative or placebo, reduce the risk of delirium, mortality, need for intubation and mechanical ventilation, or ICU length of stay (LOS) in adults with ARF initiated on NIV in the ICU? STUDY DESIGN AND METHODS: We electronically searched MEDLINE, EMBASE, and the Cochrane Library from inception through July 31, 2020, for randomized clinical trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes with the corresponding 95% CIs using a random-effect model. RESULTS: Twelve RCTs were included in our final analysis (n = 738 patients). The use of dexmedetomidine, compared with other sedation strategies or placebo, reduced the risk of intubation (RR, 0.54; 95% CI, 0.41-0.71; moderate certainty), delirium (RR, 0.34; 95% CI, 0.22-0.54; moderate certainty), and ICU LOS (MD, -2.40 days; 95% CI, -3.51 to -1.29 days; low certainty). Use of dexmedetomidine was associated with an increased risk of bradycardia (RR, 2.80; 95% CI, 1.92-4.07; moderate certainty) and hypotension (RR, 1.98; 95% CI, 1.32-2.98; moderate certainty). INTERPRETATION: Compared with any sedation strategy or placebo, dexmedetomidine reduced the risk of delirium and the need for mechanical ventilation while increasing the risk of bradycardia and hypotension. The results are limited by imprecision, and further large RCTs are needed. TRIAL REGISTRY: PROSPERO; No.: 175086; URL: www.crd.york.ac.uk/prospero/.
BACKGROUND: Although clinical studies have evaluated dexmedetomidine as a strategy to improve noninvasive ventilation (NIV) comfort and tolerance in patients with acute respiratory failure (ARF), their results have not been summarized. RESEARCH QUESTION: Does dexmedetomidine, when compared with another sedative or placebo, reduce the risk of delirium, mortality, need for intubation and mechanical ventilation, or ICU length of stay (LOS) in adults with ARF initiated on NIV in the ICU? STUDY DESIGN AND METHODS: We electronically searched MEDLINE, EMBASE, and the Cochrane Library from inception through July 31, 2020, for randomized clinical trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes with the corresponding 95% CIs using a random-effect model. RESULTS: Twelve RCTs were included in our final analysis (n = 738 patients). The use of dexmedetomidine, compared with other sedation strategies or placebo, reduced the risk of intubation (RR, 0.54; 95% CI, 0.41-0.71; moderate certainty), delirium (RR, 0.34; 95% CI, 0.22-0.54; moderate certainty), and ICU LOS (MD, -2.40 days; 95% CI, -3.51 to -1.29 days; low certainty). Use of dexmedetomidine was associated with an increased risk of bradycardia (RR, 2.80; 95% CI, 1.92-4.07; moderate certainty) and hypotension (RR, 1.98; 95% CI, 1.32-2.98; moderate certainty). INTERPRETATION: Compared with any sedation strategy or placebo, dexmedetomidine reduced the risk of delirium and the need for mechanical ventilation while increasing the risk of bradycardia and hypotension. The results are limited by imprecision, and further large RCTs are needed. TRIAL REGISTRY: PROSPERO; No.: 175086; URL: www.crd.york.ac.uk/prospero/.
Authors: Stephan M Jakob; Esko Ruokonen; R Michael Grounds; Toni Sarapohja; Chris Garratt; Stuart J Pocock; J Raymond Bratty; Jukka Takala Journal: JAMA Date: 2012-03-21 Impact factor: 56.272
Authors: Michael C Reade; Glenn M Eastwood; Rinaldo Bellomo; Michael Bailey; Andrew Bersten; Benjamin Cheung; Andrew Davies; Anthony Delaney; Angaj Ghosh; Frank van Haren; Nerina Harley; David Knight; Shay McGuiness; John Mulder; Steve O'Donoghue; Nicholas Simpson; Paul Young Journal: JAMA Date: 2016-04-12 Impact factor: 56.272
Authors: Julian Flükiger; Alexa Hollinger; Benjamin Speich; Vera Meier; Janna Tontsch; Tatjana Zehnder; Martin Siegemund Journal: Ann Intensive Care Date: 2018-09-20 Impact factor: 6.925
Authors: Fayez Alshamsi; Kallirroi Laiya Carayannopoulos; Anders Granholm; Joshua Piticaru; Kimberley Lewis; Zainab Al Duhailib; Dipayan Chaudhuri; Laura Spatafora; Yuhong Yuan; John Centofanti; Jessica Spence; Bram Rochwerg; Dan Perri; Dale M Needham; Anne Holbrook; John W Devlin; Osamu Nishida; Kimia Honarmand; Begüm Ergan; Eugenia Khorochkov; Pratik Pandharipande; Mohammed Alshahrani; Tim Karachi; Mark Soth; Yahya Shehabi; Morten Hylander Møller; Waleed Alhazzani Journal: Intensive Care Med Date: 2022-06-01 Impact factor: 41.787